---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-009922"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T22:38:51.746285+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma appoints Christopher Cooper as interim Co-CEO to boost business activities

## Summary
- Christopher Cooper appointed interim Co-CEO effective March 11, 2025; focused on capital markets and business capabilities.
- Dr. Anatoly Dritschilo continues as Chairman and Co-CEO overseeing scientific and clinical trial activities.
- Consulting agreement with Cooper's entity pays $20,000/month for six months, 40 hours/week, with 30-day termination notice.
- Cooper has 27 years of management/finance experience, raised over $100M in debt and equity for prior clients.
- Company's ongoing Phase 2 trial of Ropidoxuridine for glioblastoma continues under Dritschilo's leadership.

## SEC filing metadata
- accession: 0001493152-25-009922
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/0001493152-25-009922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-009922
- JSON: https://secwatch.observer/filing/0001493152-25-009922.json
- Plain text: https://secwatch.observer/filing/0001493152-25-009922.txt

## Source-grounded claims
- claim_id: 7795a7f75e
  claim: Christopher Cooper was appointed as interim co-Chief Executive Officer at Shuttle Pharmaceuticals Holdings, Inc..
  evidence_excerpt: On March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), appointed Mr. Christopher Cooper to the position of interim co-Chief Executive Officer (“Interim Co-CEO”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315225009922/0001493152-25-009922-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.